Page 2 of 49: studies 11 to 20 of 490, newest first. Back to the psilocybin for depression overview
Eur J Drug Metab Pharmacokinet August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Nature Medicine August 6, 2026 James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al. 1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
British Journal of Mental Health Nursing August 2, 2026 Rachel Sinclair
Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin...
EBioMedicine August 1, 2026
The use of psilocybin for treatment-resistant depression (TRD) is moving towards clinical use, and two unresolved questions will shape what comes next: how large and durable the benefit is, and what produces it? The strongest peer-reviewed efficacy signal is a phase 2b trial, in which one dose of synthetic psilocybin with psychological support approximately doubled the depression-score...
Journal of Affective Disorders August 1, 2026 Taro Kishi, Kenji Sakuma, Masakazu Hatano et al.
This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups....
Journal of Affective Disorders August 1, 2026 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 2 citations
The contribution of patient support to psilocybin's antidepressant effects remains uncertain. Relationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and EBI) and clinical outcomes (Montgomery-Åsberg Depression...
Undergraduate Research in Natural and Clinical Science and Technology Journal July 28, 2026 Danial O. Beniameen, Armya O. Beniameen
Background: Major depressive disorder (MDD) affects over 280 million people globally and remains a leading cause of disability. Psilocybin has emerged as a promising treatment, with evidence suggesting modulation of neural oscillatory activity relevant to mood regulation. Electroencephalography (EEG) and magnetoencephalography (MEG) offer non-invasive methods for evaluating these...
The Lancet Regional Health - Europe July 15, 2026 Vassilis Martiadis
The question of whether the striking antidepressant effects of psilocybin reported in randomised trials can be reproduced in everyday care remains largely unanswered. This is because those trials enrol highly selected patients, withdraw concomitant medication and deliver treatment under tightly standardised protocols. In this issue, Jungwirth et al. provide one of the first responses from...
BMJ Open July 13, 2026 Thomas D Meyer, Lauren N Vale, Maya Ibrahim et al.
Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality. Despite available guideline-based recommendations for first-line pharmacological treatments, patient outcomes remain suboptimal, especially for those with chronic depression and suicidal...
Journal of Psychedelic Studies July 13, 2026 Nils Hörnqvist
Abstract Background Research on psilocybin's antidepressant effects has been investigated rigorously over the last 20 years. Psilocybin has been used in both major depressive disorder (MDD) and treatment resistant depression (TRD) cohort with promising results. Aims The aim of this review was to summarize the reporting practices used in psilocybin-assisted therapy (PAT) trials for MDD and TRD....